CAR therapies
The tool analyzes results from standard tests of organ function, tumor burden, and inflammation to predict whether lymphoma patients will respond to treatment.
Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.
The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.
Anixa Biosciences Nabs Option to Develop Cancer Vaccines With Verdi Solutions
If Anixa exercises its rights, Verdi and Anixa will collaborate on trials in the US, while Verdi will continue developing personalized vaccines in Europe.
Autolus Reports Steady Progress for Aucatzyl's US Launch, Anticipating European Approvals in 2025
The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.